Grandem

# Grandem ## Overview - **Classification**: Novel Glycopeptide Antibiotic - **Mechanism**: Inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala precursors, disrupting peptidoglycan formation. ## Primary Indications 1. **Complicated Skin & Soft Tissue Infections (cSSTI)** - Infections caused by susceptible Gram-positive bacteria, including MRSA. 2. **Bacteremia** - Due to susceptible Gram-positive bacteria, including MRSA. 3. **Hospital-Acquired Pneumonia (HAP)** - Including Ventilator-Associated Pneumonia (VAP) caused by MRSA. ## Adult Dosing ### Standard Dosing **Complicated Skin & Soft Tissue Infections (cSSTI)** - **Dose**: **600 mg** - **Frequency**: Every 12 hours (q12h) - **Route**: Intravenous (IV) infusion over 1 hour - **Duration**: 7-14 days, based on clinical response **Bacteremia / Hospital-Acquired Pneumonia (HAP)** - **Dose**: **800 mg** - **Frequency**: Every 12 hours (q12h) - **Route**: Intravenous (IV) infusion over 1 hour - **Maximum Daily Dose**: **1600 mg** ### Dose Adjustments - **Renal Impairment**: - CrCl **30-60 mL/min**: **400 mg IV** q12h - CrCl **<30 mL/min (non-dialysis)**: **300 mg IV** q24h - **Hemodialysis (HD)**: **300 mg IV** after each HD session (3x/week) - **Hepatic Impairment**: No specific dose adjustment needed. Monitor liver function. - **Elderly Patients**: No specific adjustment, but monitor renal function closely. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **10 mg/kg** - **Frequency**: Every 24 hours (q24h) - **Maximum**: **200 mg/dose** - **Special Notes**: Monitor Grandem trough levels due to immature renal function. ### Infants (1-12 months) - **Dose**: **15 mg/kg** - **Frequency**: Every 12 hours (q12h) - **Maximum**: **400 mg/dose** ### Children (1-12 years) - **Dose**: **20 mg/kg** - **Frequency**: Every 12 hours (q12h) - **Maximum**: **800 mg/dose** (do not exceed adult single dose) ### Adolescents (13-18 years) - **Dose**: Approach adult dosing, typically **600-800 mg IV** - **Frequency**: Every 12 hours (q12h) - **Maximum**: **1600 mg/day** (adult daily maximum) ## Safety Information ### Contraindications - **Absolute**: Known hypersensitivity to Grandem or any excipients. - **Relative**: Pregnancy (weigh benefit/risk); consider alternative if possible. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, diarrhea, infusion site reactions. - **Common (1-10%)**: Rash, headache, mild transaminase elevations. - **Serious but Rare**: Nephrotoxicity, ototoxicity, "Red Man Syndrome" (rapid infusion reaction). ### Key Drug Interactions - **Nephrotoxic Drugs (e.g., aminoglycosides, NSAIDs, cyclosporine)**: Increased risk of nephrotoxicity. Monitor renal function closely. - **Ototoxic Drugs (e.g., loop diuretics)**: May increase risk of ototoxicity. Avoid concomitant use if possible. - **Warfarin**: May rarely potentiate anticoagulant effect. Monitor INR. ## Monitoring & Follow-up - **Before Treatment**: Baseline renal function (SCr, CrCl), liver enzymes (ALT/AST). - **During Treatment**: - Renal function: Daily for first 3 days, then QOD-Q3D. - Grandem trough levels: Before 3rd or 4th dose, then weekly (target **15-20 mcg/mL**). - Liver enzymes: Weekly. - **Clinical Signs**: Monitor for signs of infusion reaction, rash, hearing changes, persistent diarrhea. ## Clinical Pearls - 💡 **Infuse slowly**: Administer over at least **60 minutes** to minimize infusion-related reactions ("Red Man Syndrome"). - 💡 **Therapeutic Drug Monitoring**: Trough level monitoring is essential for efficacy and safety, especially in renal impairment. - 💡 **C. difficile Risk**: Counsel patients to report persistent diarrhea, as it may indicate _Clostridioides difficile_ infection. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.